Key Highlights

  • Moderna (NASDAQ:MRNA) rose as much as 14% on October 9, 2026 after Nasdaq announced it would rejoin the Nasdaq-100, though the size of the move conflicts across reports, ranging from 5% to 14%.
  • The stock is up about 590% year to date, a figure from a single report, which means the index news arrives after an enormous rally and a much higher base price.
  • Moderna (NASDAQ:MRNA) is rated Sell by Citigroup, so the market is pushing the price up while at least one major analyst disagrees, a contrast worth noting for risk.
  • A full melanoma trial readout is approaching, but its timing is reported and not dated, so investors face a binary event that could outweigh any benefit from index inclusion.

How Index Inclusion Moves a Stock

When a stock joins the Nasdaq-100, funds that track the index must buy it so their holdings match. Invesco QQQ Trust (NASDAQ:QQQ) and similar funds hold billions of dollars that follow this index, so inclusion creates demand that does not depend on company news. Moderna (NASDAQ:MRNA) makes medicines based on messenger RNA, and its sales fell after the pandemic vaccine boom. The Nasdaq announcement and the stock move on October 9, 2026 are verified, but the size varied from 5% to 14% depending on timing, with 14% the intraday high. Index-driven buying tends to be temporary, because once funds finish buying, the extra demand fades.

Valuation and the Analyst View

Moderna (NASDAQ:MRNA) is up about 590% year to date, based on one report. A stock that has risen 590% is worth almost seven times its starting price, simple arithmetic. Citigroup (NYSE:C) rates the shares Sell, meaning its analysts expect weaker returns than other stocks they cover. The disagreement matters because rallies built on enthusiasm can reverse when expectations meet data, and a Sell rating also carries no guarantee that the shares will fall. Moderna has needed cash to fund research, and a higher share price may give it more flexibility to raise capital, though selling shares would also dilute current holders. The company does not control how long index demand lasts or how investors respond to trial data, which can change views within minutes.

The Melanoma Readout and Risks

Moderna is developing a personalized cancer therapy for melanoma together with Merck & Co. (NYSE:MRK). A full readout from the trial is reported to be approaching, but no date is confirmed. Positive data could support the rally, while disappointing results could erase gains quickly, because the stock already prices in a lot of optimism. Other risks include weak vaccine demand, pricing pressure, changing vaccine policy and regulatory changes. Higher Treasury yields near 5.35% intraday this week also weigh on unprofitable growth companies. Investors in Moderna (NASDAQ:MRNA) should read company filings for cash levels and trial timelines, since a short-term index move says little about long-term value.

Where Things Stand

Moderna jumped because index funds had to buy it after the Nasdaq-100 announcement, and because traders are positioned ahead of a melanoma readout. Moderna (NASDAQ:MRNA) is already up about 590% for the year, while Citigroup rates it Sell, so the rally has both momentum and clear risk. The index effect may fade, and the trial result is the larger driver. The move size is confirmed only as a range of 5% to 14%, and the readout date is not set.